Management of Pregnant Women with Type 2 Diabetes Mellitus and the Consequences of Fetal Programming in Their Offspring

Current Diabetes Reports

Volumn 16, Issue 5, 2016, Pages

  Berry, Diane C ^a   Boggess, Kim ^b   Johnson, Quinetta B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Fetal programming; Poor glycemic control; Pregnancy; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; PIG INSULIN; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; BODY WEIGHT MANAGEMENT; COUNSELING; DIET THERAPY; EXERCISE; FAMILY PLANNING; FETAL PROGRAMMING; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MACROSOMIA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DEVELOPMENT; REVIEW; SELF MONITORING; WEIGHT LOSS PROGRAM; ANALYSIS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; PREGNANCY;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLYCEMIC INDEX; HUMANS; PREGNANCY; PREGNANCY OUTCOME;

EID: 84961206257     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0733-7     Document Type: Review

References (42)

1. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38 Suppl 1:S1–92. This reference gives an excellent overview of diabetes self-management.
2. American Diabetes Association, Medical management of pregnancy complicated by diabetes. 5th ed, ed. D.R. Coustan. 2013; Alexandria: American Diabetes Association. This reference gives an excellent overview of diabetes self-management in pregnant women.
3. Guariguata L et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. This reference gives projections for the future epidemic of diabetes globally.
4. International Diabetes Federation. IDF diabetes atlas—2015. 7th ed. Brussels: International Diabetes Federation; 2015.
5. Castorino K, Jovamovic L. Pregnancy and diabetes management: advances and controversies. Clin Chem. 2011;57(2):221–30.
6. Yajnik CS. Fetal programming of diabetes: still so much to learn! Diabetes Care. 2010;33(5):1146–8.
7. Portha B, Chavey A, Movassat J. Early-life origins of type 2 diabetes: fetal programming of the beta-cell mass. Exp Diabetes Res. 2011;2011:1–14. Excellent reference on fetal programming.
8. Physicians’ desk reference. 70th ed. Montvale, NJ: PDR, LLC; 2016: 2084-2093.
9. U.S. Department of Health and Human Services. Aim for a healthy weight. Bethesda, MD: U.S. Department of Health and Human Services; 2010. NIH Publication No. 10-7415.
10. Institute of Medicine. Weight gain during pregnancy: reexamining the guidelines. Washington, DC: National Academies Press; 2009.
11. American Diabetes Association. Management of diabetes in pregnancy: standards of medical care in diabetes—2015. Diabetes Care. 2015;38 Suppl 1:S77–9. Excellent reference on management of diabetes in pregnancy.
12. Gallen IW, Jaap A, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with type 1 diabetes mellitus. Diabet Med. 2008;25:165–9.
13. Imbergamo MP, Amato MC, Sciortino G, Gambina M, Accidenti M, Criscimanna A, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther. 2008;38:1476–89.
14. Kurtzhals P et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes Care. 2000;49:999–1005.
15. Jovanovic L, Druzin M, Peterson C. Effect of euglycemia on the outcome of pregnancy in insulin dependent diabetic women as compared with normal control subjects. Am J Med. 1981;71:921–7.
16. Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabetes Med. 2011;28(9):1082–7.
17. Mukherjee MS, Coppenrath VA, Dallinga BA. Pharmacologic management of types 1 and 2 diabetes mellitus and their complications in women of childbearing age. Pharmacotherapy. 2015;35(2):158–74.
18. Langer O et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–8.
19. Langer O et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol. 2005;192(1):134–9.
20. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004;190:1438–9.
21. Franz MJ, Evert A. American Diabetes Association guide to nutrition therapy for diabetes. 2nd ed. Alexandria, VA: American Diabetes Association; 2012.
22. The American College of Obstetricians and Gynecologists. Exercise during pregnancy and the postpartum period: ACOG committee opinion number 267. Washington, DC: The American College of Obstetricians and Gynecologists; 2002.
23. Harris GD, White RD. Diabetes management and exercise in pregnant patients with diabetes. Clinical Diabetes. 2005;23:165–8.
24. Tomar AS et al. Intrauterine programming of diabetes and obesity. Curr Obes Rep. 2015;4(4):418–28.
25. Barua S, Junaid MA. Lifestyle, pregnancy and epigenetic effects. Epigenomics. 2015;7(1):85–102.
26. Eriksson JG. Epidemiology, genes and the environment: lessons learned from the Helsinki Birth Cohort Study. J Intern Med. 2007;261(5):418–25.
27. Calkins K, Devaskar SU. Fetal origins of adult disease. Curr Probl Pediatr Adolesc Health Care. 2011;41(6):158–76.
28. Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 1: outcomes. Nat Rev Endocrinol. 2014;10:391–402.
29. Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 2: mechanisms. Nat Rev Endocrinol. 2014;10:403–11.
30. Pedersen J, Osler M. Hyperglycemia as the cause of characteristic feature of the foetus and newborn of diabetic mothers. Dan Med Bull. 1961;8:78–83.
31. Freinkel N. Of pregnancy and progeny. Diabetes. 1980;29:1023–35.
32. Hales CN et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991;303:1019–22.
33. McCance DR et al. Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ. 1994;308(6934):942–5.
34. Whincup PH et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA. 2008;300(24):2886–97.
35. Uribarri J et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34(7):1610–6.
36. Tang Z et al. Placental Hofbauer cells and complications of pregnancy. Ann NY Acad Sci. 2011;1221:103–8.
37. Clausen TD et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31(2):340–6.
38. HAPO Study Cooperative Research Group et al. Hypertensive and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.
39. Pettitt DJ et al. Maternal glucose at 28 weeks of gestation is not associated with obesity in 2-year-old offspring: the Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) family study. Diabetes Care. 2010;33(6):1219–23.
40. Lindsay RS et al. Programming of adiposity in offspring of mothers with type 1 diabetes at age 7 years. Diabetes Care. 2010;33:1080–5.
41. Gillman MW et al. Effect of treatment of gestational diabetes on obesity in the next generation. Diabetes Care. 2010;33:964–8.
42. Pirkola J et al. Risks of overweight and abdominal obesity at age 16 years associated with prenatal exposures to maternal prepregnancy overweight and gestational diabetes mellitus. Diabetes Care. 2010;33(5):1115–21.